Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10938071 | 1.00 | TSHR (0.42) | TSHRALDH1A1CYP3A4THRBHTT | |
| SCHEMBL5176031 | 0.94 | ALDH1A1 (0.39) | TSHRALDH1A1CYP3A4THRBHTT | |
| SCHEMBL4267544 | 0.94 | ALDH1A1 (0.39) | TSHRALDH1A1CYP3A4THRBHTT | |
| SCHEMBL4396035 | 0.94 | ALDH1A1 (0.39) | TSHRALDH1A1CYP3A4THRBHTT | |
| SCHEMBL4863 | 0.94 | — | — | |
| SCHEMBL4395126 | 0.92 | TSHR (0.41) | TSHRALDH1A1CYP3A4THRBHTT | |
| SCHEMBL21435871 | 0.92 | — | — | |
| SCHEMBL7335503 | 0.90 | THRB (0.43) | TSHRALDH1A1CYP3A4THRBHTT | |
| SCHEMBL11222954 | 0.90 | THRB (0.43) | TSHRALDH1A1CYP3A4THRBHTT | |
| SCHEMBL4393806 | 0.89 | ALDH1A1 (0.39) | TSHRALDH1A1CYP3A4THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976185-B1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) | 2024-02-14 | — | — | EP | disclosed |
| EP-3976185-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020245213-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2020-12-10 | — | — | WO | disclosed |
| EP-3216796-B1 | PHOSPHONIUM COMPOUND AND PRODUCTION METHOD THEREFOR | UNIV TOHOKU (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-20180030074-A1 | PHOSPHONIUM COMPOUND AND PRODUCTION METHOD THEREFOR | TOHOKU UNIVERSITY (JP) | 2018-02-01 | — | — | US | disclosed |
| EP-3216796-A1 | PHOSPHONIUM COMPOUND AND PRODUCTION METHOD THEREFOR | Tohoku University (JP) | 2017-09-13 | — | — | EP | disclosed |
| US-8017670-B2 | Epoxy resin composition for optical-semiconductor encapsulation, cured resin thereof, and optical semiconductor device obtained with the same | NITTO DENKO CORPORATION (JP) | 2011-09-13 | — | — | US | disclosed |
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100041799-A2 | Epoxy Resin Composition for Optical-Semiconductor Encapsulation, Cured Resin Thereof, and Optical Semiconductor Device Obtained with the same | NITTO DENKO CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | MITSUI CHEMICALS, INC. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-0628607-A2 | Naphthalocyanine | BASF Aktiengesellschaft (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0619346-A1 | Lacquered tris-or tetracationic polymethin dyes | BASF Aktiengesellschaft (DE) | 1994-10-12 | — | — | EP | disclosed |
| WO-1994021471-A1 | INK RIBBONS CONTAINING COMPOUNDS ABSORBING IN THE IR REGION | BASF AKTIENGESELLSCHAFT (DE) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994002570-A1 | USE OF COMPOUNDS WHICH ABSORB AND/OR FLUORESCE IN THE I/R RANGE AS MARKERS FOR LIQUIDS | BASF AKTIENGESELLSCHAFT (DE) | 1994-02-03 | — | — | WO | disclosed |
| US-5282894-A | Use of a liquid containing IR dyes as printing ink | BASF AKTIENGESELLSCHAFT (DE) | 1994-02-01 | — | — | US | disclosed |
| EP-0561639-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 1993-09-22 | — | — | EP | disclosed |
| EP-0553614-A1 | Use of infrared dyes containing liquid as a printing ink | BASF Aktiengesellschaft (DE) | 1993-08-04 | — | — | EP | disclosed |
| US-5205838-A | LIQUID DYE PREPARATIONS: BIS PHENYL-AZO-RESORCINOL IN SOLVENT FOR COLORED RIBBON OR BALL PEN INK | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| EP-0501167-A1 | Liquid dye preparations | BASF Aktiengesellschaft (DE) | 1992-09-02 | — | — | EP | disclosed |
| US-4386935-A | Process for producing discharge reserve prints on textile materials with amino-azo-benzene dyes | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | CACNA1B, KCNN4, KCNN2 | TSHR 3610/4885ALDH1A1 4231/4885CYP3A4 2777/4885 |
| US-20180030074-A1 | PHOSPHONIUM COMPOUND AND PRODUCTION METHOD THEREFOR | PHPT1, PHOSPHO1, WEE1 | TSHR 1193/4885ALDH1A1 1544/4885CYP3A4 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.